Daily Cardiology Research Analysis
Analyzed 143 papers and selected 3 impactful papers.
Summary
Three high-impact cardiology studies span basic, translational, and clinical innovation: (1) a JCI mechanistic study shows that unrestrained cardiac fatty acid oxidation depletes cardiolipin and precipitates heart failure, reversible by FAO inhibition; (2) targeted intra-atrial delivery of GMP-grade human extracellular vesicles prevented postoperative atrial fibrillation in large animals; and (3) 10°C static cold storage in heart transplantation decouples ischemic time from severe primary graft dysfunction, potentially expanding safe transport windows.
Research Themes
- Mitochondrial lipid metabolism and cardiomyopathy
- Organ preservation and perioperative innovation in cardiac transplantation
- Translational biologics for arrhythmia prevention
Selected Articles
1. Unrestrained fatty acid oxidation triggers heart failure in mice via cardiolipin loss and mitochondrial dysfunction.
Cardiomyocyte-specific ACC1/ACC2 deletion caused constitutively elevated FAO that depleted cardiolipin via reduced linoleic acid, impairing ETC function and leading to heart failure. Pharmacologic FAO inhibition restored cardiolipin, normalized mitochondrial activity, and prevented cardiac dysfunction, cautioning against strategies that stimulate cardiac FAO in heart failure.
Impact: This work uncovers a causal, targetable link between excessive FAO, cardiolipin depletion, and heart failure, and demonstrates rescue with two FAO inhibitors, reframing metabolic strategies in heart failure.
Clinical Implications: Therapeutic approaches that stimulate cardiac FAO may be harmful in heart failure. Modulating FAO or preserving cardiolipin/linoleic acid homeostasis could be explored as disease-modifying strategies, pending human validation and safer FAO modulators.
Key Findings
- Cardiomyocyte ACC1/ACC2 double knockout mice developed dilated cardiomyopathy and heart failure under constitutively elevated FAO.
- Lipidomics showed cardiolipin depletion driven by reduced linoleic acid, impairing ETC activity and mitochondrial function.
- FAO inhibitors (etomoxir or oxfenicine) restored cardiolipin, normalized ETC activity, and prevented cardiac dysfunction in the model.
Methodological Strengths
- Genetic loss-of-function model with in vivo phenotyping and multi-omics (lipidomics) readouts
- Pharmacologic rescue with two independent FAO inhibitors strengthens causal inference
Limitations
- Findings are preclinical (mouse) and may not fully translate to humans
- Etomoxir has known off-target effects; safety and specificity of FAO modulation in humans remain uncertain
Future Directions: Validate cardiolipin remodeling and FAO modulation in human myocardium; develop safer, selective FAO modulators; test dietary/therapeutic strategies that preserve linoleic acid–cardiolipin homeostasis in heart failure.
Cardiomyocytes primarily rely on fatty acid oxidation (FAO), which provides more than 70% of their energy. However, excessive FAO can disrupt cardiac metabolism by increasing oxygen demand and suppressing glucose utilization through the Randle cycle. Although inhibition of FAO has been investigated in heart failure, its overall therapeutic impact remains uncertain. To determine the consequences of enhanced FAO, we generated cardiomyocyte-specific ACC1 and ACC2 double-knockout (ACC dHKO) mice, which exhibit constitutively elevated FAO. ACC dHKO mice developed dilated cardiomyopathy and heart failure. Lipidomic analysis revealed marked depletion of cardiolipin caused by reduced linoleic acid, a direct consequence of excessive FAO. This cardiolipin deficiency impaired mitochondrial electron transport chain (ETC) activity, leading to mitochondrial dysfunction. Pharmacologic inhibition of FAO with etomoxir or oxfenicine restored cardiolipin levels, normalized ETC activity, and prevented cardiac dysfunction in ACC dHKO mice. These findings demonstrate that unrestrained FAO disrupts both lipid and energy homeostasis, culminating in heart failure in this model. Collectively, these results indicate that although FAO is essential for cardiac energy production, therapeutic strategies aimed at stimulating cardiac FAO may be detrimental rather than beneficial in heart failure.
2. Targeted Intra-Atrial Delivery of GMP-Grade Human Extracellular Vesicles Prevents Inflammation-Driven Postoperative Atrial Fibrillation in Pigs.
In rat and porcine sterile pericarditis models, atrial-targeted delivery of GMP-grade human cardiac EVs achieved selective atrial retention, showed no systemic toxicity, completely prevented spontaneous AF in pigs, reduced inducible AF, and attenuated atrial inflammation and fibrosis.
Impact: This translational large-animal study demonstrates a first-in-human–ready, localized biologic that prevents postoperative AF, addressing a major unmet perioperative need with a novel cell-free therapy.
Clinical Implications: If validated in humans, atrial-targeted EV therapy could offer a disease-modifying, device-free approach to prevent postoperative AF, potentially reducing ICU burden, rehospitalizations, and atrial remodeling.
Key Findings
- GMP-grade human cardiac EVs showed selective atrial retention and no systemic toxicity after intra-atrial delivery in rats.
- In pigs, EV therapy completely prevented spontaneous postoperative AF and significantly reduced inducible AF.
- EV treatment attenuated atrial inflammation and fibrosis without adverse end-organ effects.
Methodological Strengths
- Use of GMP-compatible, serum/xeno-free manufactured EVs enhances translational readiness
- Efficacy demonstrated in a large-animal (porcine) model with clinically relevant postoperative AF physiology
Limitations
- Preclinical models (sterile pericarditis) may not capture all drivers of human postoperative AF
- Durability, optimal dosing, and comparative effectiveness versus standard antiarrhythmic strategies are not yet defined
Future Directions: Proceed to phase I safety and feasibility studies with atrial-targeted EV delivery; define dose, timing, and perioperative workflows; evaluate anti-inflammatory mechanisms and biomarker-guided patient selection.
Targeted intra-atrial delivery of GMP-grade human cardiac extracellular vesicles (EVs) was evaluated for prevention of postoperative atrial fibrillation (AF). EVs were manufactured under serum-free, xenogen-free GMP-compatible conditions and tested in rat and porcine sterile pericarditis models. In rats, intra-atrial EV delivery resulted in selective atrial retention without systemic toxicity. In pigs, EV administration was technically feasible, well tolerated, and completely prevented spontaneous AF while significantly reducing inducible AF. EV therapy also attenuated atrial inflammation and fibrosis without adverse end-organ effects. These findings support localized cardiac EV therapy as a first-in-human-ready, disease-modifying biologic strategy for postoperative AF prevention.
3. From Constraint to Opportunity: 10°C Static Cold Storage Allows Prolonged Ischemic Time and Attenuates Severe Primary Graft Dysfunction Risk in Adult Heart Transplantation.
In 506 adult heart transplants, 10°C static cold storage flattened the ischemic-time risk curve for severe PGD. Compared with ice, 10°C storage markedly reduced severe PGD odds at 4 hours (OR 0.21) and yielded a 90.9% relative risk reduction beyond 4 hours, despite longer ischemic times and older donor hearts.
Impact: This practice-changing preservation strategy could safely extend ischemic times, expand donor catchment, and reduce severe PGD, with rigorous causal analyses supporting the signal in real-world data.
Clinical Implications: Adopting 10°C static cold storage could extend safe transport windows beyond 4 hours, reduce severe PGD risk, improve early graft function, and potentially increase organ utilization, pending multicenter validation.
Key Findings
- Among 506 recipients, 10°C storage was associated with significantly lower odds of severe PGD at 4 hours of ischemia versus ice (OR 0.21; 95% CI 0.09–0.45).
- Each additional hour of ischemia with ice increased severe PGD odds 2.7-fold; the ischemic-time risk curve flattened under 10°C storage.
- In ischemic time >4 hours, 10°C yielded a 90.9% relative risk reduction in severe PGD; mediation analysis showed a net risk reduction of 3.5 percentage points.
Methodological Strengths
- Large contemporary cohort with prespecified outcomes and advanced causal inference (weighted regression, g-computation, mediation analysis)
- Clinically meaningful endpoints (severe PGD, early function, mortality) with robust effect modification by ischemic time
Limitations
- Single-center retrospective design with potential residual confounding and selection bias
- Nonrandomized allocation to storage strategy; learning curves and logistics may influence outcomes
Future Directions: Prospective multicenter trials to validate efficacy and safety; define logistics and quality standards for 10°C storage; evaluate long-term graft function and survival and cost-effectiveness.
BACKGROUND: Allograft ischemic time remains a major constraint in heart transplantation, with ice-based static cold storage (SCS) limiting safe transport to 4 hours. We evaluated whether 10°C SCS alters the relationship between ischemic time and early cardiac allograft function in a contemporary single-center cohort. METHODS: We retrospectively analyzed adult heart transplants performed from January 2020 to June 2025. Only allografts preserved with SCS (ice or 10°C) were included; multiorgan and complex congenital transplants were excluded. The primary exposure was preservation strategy (ice vs 10°C) and total allograft ischemic time. The primary outcome was severe primary graft dysfunction (PGD); secondary outcomes included early biventricular function, vasoactive inotrope score, renal replacement therapy, length of stay, and 30- and 90-day mortality. Weighted regression assessed the effect of ischemic time and its interaction with storage type on severe PGD. In a prespecified subgroup with ischemic time >4 hours, g-computation estimated counterfactual risks if all grafts had been stored at 10°C. Regression-based causal mediation analysis quantified the net effect of prolonged ischemic time with 10°C SCS on severe PGD. RESULTS: Among 506 recipients (median age 58.3 years; 25.5% female), 40.9% received 10°C-preserved grafts and 59.1% received ice-preserved grafts. Compared with ice, the 10°C cohort more often received hearts from older donors (36.0 vs 29.9 years; p<0.001) with longer ischemic times (235 vs 202 minutes; p<0.001), yet early outcomes were similar overall. In weighted models, each additional hour of ischemia in ice-preserved grafts increased the odds of severe PGD by 2.7-fold (p<0.001). At 4 hours of ischemic time, 10°C storage was associated with markedly lower odds of severe PGD compared with ice (OR 0.21; 95% CI 0.09-0.45; p<0.001) and the ischemic time risk curve flattened in 10°C cohort. In the ischemic time >4-hour subgroup, 10°C corresponded to a relative risk reduction in severe PGD of 90.9% (95% CI 59.7-99.5). Mediation analysis estimated a net risk reduction in severe PGD of 3.5 percentage points for 10°C vs ice (95% CI -7.7 to -0.2; p=0.042) despite accumulating high ischemic time risk. CONCLUSIONS: In this contemporary cohort, 10°C SCS decoupled the traditional link between prolonged ischemic time and severe PGD. 10°C preservation conferred a net reduction in severe PGD and improved early graft performance compared with ice in adult heart transplantation.